“A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People With Overweight/Obesity”, Carel Le Roux, Oren Steen, Kathryn J. Lucas, Elena Startseva, Anna Unseld, Anita M. Hennige2023-06-23 (; backlinks)⁠:

Glucagon receptor (GCGR) agonism increases energy expenditure and glucagon-like peptide 1 receptor (GLP-1R) agonism reduces energy intake; thus, dual GCGR/GLP-1R agonists, such as BI 456906, may be more effective at treating obesity than mono GLP-1R agonists

This double-blind, placebo (PBO)-controlled study (NCT04667377) randomized adults with BMI ≥27 kg⁄m2 to weekly subcutaneous BI 456906 (0.6, 2.4, 3.6, 4.8 mg) or PBO for 46 weeks.

…BI 456906 therapeutic benefit vs PBO was shown by a non-flat dose response curve of BW change (%) from BL at W46. Mean BW reduced with dose over 46 weeks (FAS; 0.6 mg, −6.2%; 2.4 mg, −12.5%; 3.6 mg, −13.2%; 4.8 mg, −14.9%; vs PBO, −2.8%)…Participants reaching and staying on 4.8 mg BI 456906 achieved BW loss of 18.7% at W46.

…Over 46 weeks, BI 456906 showed substantial BW loss efficacy with no unexpected safety concerns.

View HTML:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People With Overweight/Obesity